Delving into the Latest Updates on Beijing LiangYuan Bioscience LLC. with Synapse

Overview

Tags

Neoplasms

Hemic and Lymphatic Diseases

Cytokines

Antibody

Therapeutic vaccine

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	3
Hemic and Lymphatic Diseases	1

Top 5 Drug Type	Count

Cytokines	2
Antibody	1
Therapeutic vaccine	1
Oligonucleotide	1

Top 5 Target	Count

IL-2R(Interleukin-2 receptor)	1
MUC1(Mucin-1)	1
G-CSF(Granulocyte colony-stimulating factor)	1

Ia期剂量递增阶段主要目的： 1) 评价LYC001在晚期实体瘤受试者中的安全性和耐受性； 2) 确定最大耐受剂量（MTD，若存在）和/或扩展阶段推荐剂量（RDE）。次要目的： 1) 评价LYC001在晚期实体瘤受试者中的药代动力学特征； 2) 评价LYC001在晚期实体瘤受试者中的免疫原性。 Ib期扩展阶段主要目的： 1) 评价在RDE剂量下LYC001在晚期实体瘤受试者中的安全性和耐受性； 2) 确定后续II期临床研究的推荐剂量（RP2D）。次要目的： 1) 评价在RDE剂量下LYC001在晚期实体瘤受试者中的药代动力学特征； 2) 评价LYC001在晚期实体瘤受试者中的免疫原性； 3) 评价在RDE剂量下LYC001给药晚期实体瘤受试者的初步有效性。

[Translation]

Phase Ia Dose-Escalation Phase Primary Objectives: 1) Evaluate the safety and tolerability of LYC001 in subjects with advanced solid tumors; 2) Determine the maximum tolerated dose (MTD, if available) and/or recommended dose for expansion (RDE). Secondary Objectives: 1) Evaluate the pharmacokinetic profile of LYC001 in subjects with advanced solid tumors; 2) Evaluate the immunogenicity of LYC001 in subjects with advanced solid tumors. Phase Ib Extension Phase Primary Objectives: 1) Evaluate the safety and tolerability of LYC001 at the RDE dose in subjects with advanced solid tumors; 2) Determine the recommended dose (RP2D) for subsequent Phase II clinical studies. Secondary Objectives: 1) Evaluate the pharmacokinetic profile of LYC001 at the RDE dose in subjects with advanced solid tumors; 2) Evaluate the immunogenicity of LYC001 in subjects with advanced solid tumors; 3) Evaluate the preliminary efficacy of LYC001 at the RDE dose in subjects with advanced solid tumors.

Start Date-

Sponsor / Collaborator

Beijing LiangYuan Bioscience LLC.

100 Clinical Results associated with Beijing LiangYuan Bioscience LLC.

Login to view more data

0 Patents (Medical) associated with Beijing LiangYuan Bioscience LLC.

Login to view more data

100 Deals associated with Beijing LiangYuan Bioscience LLC.

Login to view more data

100 Translational Medicine associated with Beijing LiangYuan Bioscience LLC.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 03 Nov 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

4

1

Phase 1

Login to view more data